Effects of Daily Beef Intake, as a Component of a Heart-Healthy Diet on Cellular Zinc

Inflammation Clinical Trial

Official title:

Effects of Daily Beef Intake, as a Component of a Heart-Healthy Diet, on Cellular Zinc Status and Vascular Function in Older Adults

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05236374
• Other study ID #: 1806393
• Status: Recruiting
• Phase: N/A
• Start date: October 1, 2022
• Est. completion date: September 4, 2025

Study information

• Verified date: May 2023
• Source: University of California, Davis
• Contact: Roberta R Holt, PhD
• Phone: 15304005952
• Email: rrholt[@]ucdavis.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of the current study is to test the overarching hypothesis that the beef nutritive matrix is uniquely suited to direct dietary zinc to cellular compartments for improved metabolic function, leading to a greater effect on health outcomes. Specifically, whether beef, as a component of a healthy meal, will promote the absorption of zinc into cells, where the zinc will have greater effects on zinc-dependent metabolic processes supporting cardiovascular health. To maximize the observability of these beef-related effects, individuals who are 55- to 70-year-old who generally have a higher risk of zinc deficiency and cardiovascular disease will be enrolled.

Description:

This study will examine whether daily beef intake will promote the absorption of dietary zinc into cells, leading to improved cellular zinc status and microvascular function. The study design will be a crossover comparison of a mixed diet including green leafy vegetables, fruits, whole grains, seeds, and nuts; with beef versus non-meat sources of additional protein and zinc, over two 4-week metabolic study periods.

Outcomes will include cellular zinc status determined by erythrocyte zinc tracer exchange (primary), and microvascular function expressed as reactive hyperemia index (RHI). Previous studies have demonstrated that zinc tracer exchange with red blood cells (RBC) is highly sensitive to changes in zinc nutriture. Thus, cellular zinc status will be determined using a novel and cost-effective adaptation of this approach, modeling zinc tracer exchange with freshly-sampled RBC. As intracellular zinc can regulate vascular tone, microvascular function will be measured, using digital peripheral tonometry, will be used as a functional index of both cellular zinc status and vascular health.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: September 4, 2025
• Est. primary completion date: September 4, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 55 Years to 70 Years

Eligibility

Inclusion Criteria:

• Male or postmenopausal female 55-70 years of age

• Women: lack of menses for at least two years.

• Subject is willing and able to comply with the study protocols.

• Subject is willing to participate in all study procedures

• Self-reported stable dose of prescribed medications for a minimum of 6 months

• BMI 18.5 - 29.9 kg/m2

Exclusion Criteria:

• Self-reported use of daily anticoagulation agents including aspirin, NSAIDs

• Prescribed metaformin, statins or medications known to interfere with zinc, protein, or lipid metabolism

• Vegan, Vegetarians, food faddists or those consuming a non-traditional diet (e.g. Adkins, Keto, Paleo, etc.)

• Fruit consumption = 3 cups/day

• Regular consumption of strawberries (2-3 servings/week)

• Vegetable consumption = 4 cups/day

• Coffee/tea = 3 cups/day

• Dark chocolate = 3 oz/day

• Alcohol intake greater than 2 drinks in a day for men, or 1 drink in a day for women.

• Self-reported restriction of physical activity due to a chronic health condition

• Self-reported chronic/routine high intensity exercise

• Self-reported diabetes

• Blood pressure = 140/90 mm Hg

• Self-reported renal or liver disease

• Self-reported heart disease, which includes cardiovascular events and stroke

• Peripheral artery disease Raynaud's syndrome or disease

• Inability to properly place or wear the PAT probes or abnormal measurements on pre-screening PAT

• Self-reported cancer within past 5 years

• Self-reported malabsorption

• Unwillingness to stop any supplement use six weeks prior to study initiation, including multivitamin/mineral, powders, herbal, plant or botanical, pro- and prebiotics, and oil supplements.

• Smoking, vaping, cannabis use

• Current enrollee in a clinical research study.

Related Conditions & MeSH terms

• Inflammation
• Metabolic Diseases
• Vascular Diseases
• Zinc Deficiency

Intervention

Other:
• Beef protein
Animal protein source

Locations

Country	Name	City	State
United States	University of California, Davis; Department of Nutrition	Davis	California

Sponsors (2)

Lead Sponsor	Collaborator
University of California, Davis	National Cattlemen's Beef Association

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	microvascular function	microvascular function as measured by digital tonometry (EndoPAT2000)	4 weeks
Primary	intracellular zinc status	intracellular zinc status determined by erythrocyte zinc tracer exchange	4 weeks
Secondary	plasma lipids	Circulating level of total cholesterol, triglycerides, HDL cholesterol, non-HDL cholesterol, with LDL cholesterol (calculated)	4 weeks
Secondary	plasma fatty acids	Circulating levels of non-esterified fatty acids	4 weeks
Secondary	plasma oxylipins	enzyme and non-enzyme derived non-esterified fatty acid metabolites	4 weeks